Coloplast A/S

BATS-CHIXE:COLOBC Stock Report

Market Cap: DKK 135.7b

Coloplast Valuation

Is COLOBC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COLOBC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
DKK 1.00k
Fair Value
39.9% undervalued intrinsic discount
18
Number of Analysts

Below Fair Value: COLOBC (DKK602.8) is trading below our estimate of fair value (DKK1002.85)

Significantly Below Fair Value: COLOBC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COLOBC?

Key metric: As COLOBC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for COLOBC. This is calculated by dividing COLOBC's market cap by their current earnings.
What is COLOBC's PE Ratio?
PE Ratio29.9x
EarningsDKK 4.54b
Market CapDKK 135.73b

Price to Earnings Ratio vs Peers

How does COLOBC's PE Ratio compare to its peers?

The above table shows the PE ratio for COLOBC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average41.5x
CTEC ConvaTec Group
38.7x16.89%UK£5.4b
AMS Advanced Medical Solutions Group
62.8x39.17%UK£445.4m
SN. Smith & Nephew
32.2x16.35%UK£9.7b
TSTL Tristel
32.3x19.05%UK£198.5m
COLOBC Coloplast
29.9x16.26%DKK 135.7b

Price-To-Earnings vs Peers: COLOBC is good value based on its Price-To-Earnings Ratio (29.9x) compared to the peer average (41.5x).

Price to Earnings Ratio vs Industry

How does COLOBC's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies10PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: COLOBC is good value based on its Price-To-Earnings Ratio (29.9x) compared to the European Medical Equipment industry average (32.5x).

Price to Earnings Ratio vs Fair Ratio

What is COLOBC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COLOBC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate COLOBC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COLOBC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 602.80
DKK 737.89
+22.41%
10.89%DKK 962.00DKK 600.00n/a18
Jun ’26DKK 639.60
DKK 751.95
+17.57%
10.83%DKK 962.00DKK 640.00n/a19
May ’26DKK 728.00
DKK 896.20
+23.10%
11.46%DKK 1,050.00DKK 694.00n/a20
Apr ’26n/a
DKK 910.71
0%
10.85%DKK 1,050.00DKK 700.00n/a21
Mar ’26DKK 777.60
DKK 909.76
+17.00%
10.85%DKK 1,050.00DKK 700.00n/a21
Feb ’26DKK 834.00
DKK 911.43
+9.28%
10.74%DKK 1,030.00DKK 700.00n/a21
Jan ’26n/a
DKK 924.43
0%
9.41%DKK 1,030.00DKK 700.00n/a21
Dec ’25DKK 893.60
DKK 924.67
+3.48%
9.44%DKK 1,030.00DKK 700.00n/a21
Nov ’25DKK 862.20
DKK 913.33
+5.93%
11.03%DKK 1,050.00DKK 700.00n/a21
Oct ’25DKK 874.00
DKK 913.60
+4.53%
11.03%DKK 1,060.00DKK 700.00n/a20
Sep ’25DKK 920.10
DKK 911.35
-0.95%
11.26%DKK 1,060.00DKK 700.00n/a20
Aug ’25DKK 886.60
DKK 905.90
+2.18%
10.97%DKK 1,060.00DKK 710.00n/a20
Jul ’25n/a
DKK 895.40
0%
10.53%DKK 1,060.00DKK 710.00DKK 597.8020
Jun ’25DKK 815.40
DKK 909.89
+11.59%
10.22%DKK 1,060.00DKK 710.00DKK 639.6019
May ’25DKK 858.40
DKK 917.05
+6.83%
10.86%DKK 1,060.00DKK 700.00DKK 728.0019
Apr ’25DKK 934.80
DKK 897.32
-4.01%
10.26%DKK 1,060.00DKK 700.00n/a19
Mar ’25n/a
DKK 871.79
0%
10.07%DKK 1,000.00DKK 700.00DKK 777.6019
Feb ’25DKK 799.10
DKK 823.74
+3.08%
9.81%DKK 962.00DKK 631.00DKK 834.0019
Jan ’25n/a
DKK 816.56
0%
10.25%DKK 962.00DKK 631.00n/a18
Dec ’24DKK 799.90
DKK 817.67
+2.22%
10.11%DKK 962.00DKK 631.00DKK 893.6018
Nov ’24n/a
DKK 848.78
0%
9.20%DKK 980.00DKK 686.00DKK 862.2018
Oct ’24n/a
DKK 865.24
0%
9.89%DKK 1,000.00DKK 686.00DKK 874.0017
Sep ’24DKK 799.60
DKK 907.53
+13.50%
10.13%DKK 1,070.00DKK 720.00DKK 920.1015
Aug ’24DKK 847.10
DKK 928.88
+9.65%
9.93%DKK 1,070.00DKK 720.00DKK 886.6016
Jul ’24DKK 834.00
DKK 915.44
+9.76%
11.05%DKK 1,070.00DKK 690.00n/a16
AnalystConsensusTarget
Consensus Narrative from 18 Analysts
DKK 737.89
Fair Value
18.3% undervalued intrinsic discount
18
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/07 14:44
End of Day Share Price 2025/07/04 00:00
Earnings2025/03/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Coloplast A/S is covered by 52 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Robert BateBarclays
Alexander KlebanBarclays